Fueling hope in Charcot-Marie-Tooth disease through transformative clinical trial partnerships

Charcot–Marie–Tooth (CMT) disease has been recognized for more than a century, yet there are still no approved disease-modifying therapies available to the millions of people worldwide living with this inherited peripheral neuropathy. CMT encompasses a diverse group of genetic disorders that affect the peripheral nerves, leading to progressive muscle weakness, sensory loss, balance issues and functional impairment. While often described as a “rare disease,” CMT is among the most common inherited neurological conditions, affecting an estimated one in 2,500 people in the United States. But relatively low public awareness and a wide spectrum of disease presentations have made it difficult to build the level of unified research momentum that has gathered behind other neuromuscular disorders.

That dynamic is changing. Advances in genetics and molecular science, an increase in early phase clinical trial activity, and growing industry participation are converging to create a renewed sense of optimism among patients and advocates.

However, hope alone does not move therapies across the finish line. Clinical trial complexity remains a barrier to translating scientific progress into approved treatments. Navigating that complexity thoughtfully, collaboratively and with patients at the center will determine whether this momentum becomes a true turning point.

Understanding the evolving CMT research landscape

The CMT research landscape has transformed significantly over the past two decades. More than 100 genes have now been identified in relation to CMT, highlighting the extraordinary genetic heterogeneity of the disease. What was once viewed as a single condition is now understood as a collection of subtypes, each with distinct biological mechanisms.

This deeper molecular understanding has opened the door to targeted therapeutic approaches. Researchers are exploring small molecules aimed at modulating protein expression, as well as gene and RNA-based therapies designed to correct or compensate for underlying genetic defects. Meanwhile, disease-specific outcome measures and assessment tools have been developed to better capture impairment and function in CMT populations.

Clinical trial activity reflects this evolution as early phase studies increase and industry investment grows. Lessons learned from progress in related neuromuscular diseases such as spinal muscular atrophy and Duchenne muscular dystrophy are informing development strategies, regulatory pathways, and endpoint selection in CMT.

From the patient perspective, this shift is substantial. Advocacy organizations are investing in registries, natural history studies and educational initiatives to prepare the community for greater trial participation. There is a shared sense among patients and researchers alike that CMT may be approaching an inflection point where decades of foundational science could begin translating into tangible therapies. However, the inherent variability and complexity of CMT continues to shape the clinical development pathway.

The reality of the CMT patient experience

Some CMT advocates summarize the nature of the disease with the phrase, “if you’ve met one CMT patient, you’ve met one CMT patient.” Because the disease presents differently across subtypes, families, and individuals, symptom severity and progression can vary widely, even within the same family sharing the same genetic mutation. Some individuals experience early-onset motor impairment, while others develop milder symptoms later in life. Sensory symptoms, balance issues, neuropathic pain, muscle weakness, and fatigue can all present on different timelines and intensities.

Adding to this heterogeneity is day-to-day variability. Many patients describe “good days” and “bad days” that may not correlate neatly with measurable disease progression. Subtle changes in coordination, grip strength or balance may dramatically affect quality of life but remain difficult to capture with traditional functional tests.

The diagnostic journey can be equally challenging with misdiagnosis, delayed genetic testing and long referral pathways being common especially for non-classic or rare subtypes. For many, the emotional burden of uncertainty, hereditary risk and concern for future generations adds another layer of complexity.

In clinical research, this heterogeneity complicates patient selection, endpoint sensitivity, and statistical analysis, making it difficult to plan studies and interpret trial outcomes. Despite these challenges, many patients are eager to engage by participating in trials, contributing to registries, and advancing understanding among those who may not directly benefit from a specific study.

Challenges in designing and executing CMT clinical trials

Endpoint selection and sensitivity

Selecting appropriate endpoints in CMT trials is particularly complex. Traditional functional measures like walking tests or strength assessments provide important data but may not fully capture functional changes that are meaningful to patients. Conversely, snapshot assessments can struggle to account for daily variability, and small but meaningful improvements in dexterity, balance, or fatigue may not register clearly in standardized scales.

Adding to this challenge is the need for robust natural history data. Without well-characterized progression patterns across subtypes, it becomes difficult to validate endpoints, interpret treatment effects, or confidently design studies. Natural history datasets provide the context necessary to distinguish true therapeutic impact from underlying variability and slow disease progression while also strengthening regulatory confidence in outcome measures. Encouragingly, patients are often willing to participate in long-term observational studies especially when the purpose and potential impact are clearly communicated.

A growing interest in secondary and exploratory endpoints aims to address the need for more effective outcome measures. Emerging tools such as advanced imaging, digital assessments, wearable sensors, and patient-reported outcomes offer promise in capturing more nuanced disease changes. However, validation, standardization and regulatory alignment remain essential.

Trial duration and participant burden

CMT typically progresses slowly, providing an opportunity for early intervention but also necessitating longer clinical trials to detect meaningful change. Longer trials increase operational complexity, cost and feasibility challenges. For patients, extended participation can introduce fatigue, travel burden and life disruptions. Retention becomes a key factor, particularly in rare disease populations where recruitment pools are already limited. Mitigating these burdens requires thoughtful planning, consistent site training and patient-centric operational strategies.

Eligibility constraints and patient frustration

Interest in CMT trial participation is strong but eligibility criteria can be restrictive. Disease stage requirements, subtype specificity, and functional thresholds may exclude patients who are eager to participate, which can lead to frustration and misunderstanding. Importantly, ineligibility for a specific trial does not equate to ineligibility for a future therapy, but clear communication is essential to maintain trust and engagement. Education and expectation-setting play a critical role in sustaining long-term patient support.

Additionally, many CMT subtypes begin in childhood, yet pediatric trials remain limited. Ethical, logistical, and methodological considerations contribute to this gap, but early intervention may offer the greatest opportunity to preserve nerve function and prevent long-term disability. Expanding pediatric readiness, including appropriate outcome measures and operational frameworks, will be critical for future development strategies.

How the right partner can help navigate CMT trial complexity

Successfully navigating CMT trial complexity requires more than promising science — it demands experience, operational precision and partnership.

Designing patient-informed, subtype-aware trials

The genetic and phenotypic heterogeneity of CMT makes thoughtful trial design essential. This includes incorporating genetic and phenotypic stratification approaches that account for subtype variability, identifying appropriate strategies, and designing adaptive or flexible trial models. Early regulatory engagement and scientific consultation help align innovative endpoints with approval requirements, balancing scientific rigor with patient relevance.

By integrating clinical, statistical, and patient-centered expertise, the PPD™ clinical research business of Thermo Fisher Scientific ensures studies measure outcomes that are both regulatorily sound and meaningful to the people living with CMT.

Partnering with patient advocacy organizations

Strong patient engagement in rare disease is foundational. Therefore, a smart approach emphasizes early and ongoing collaboration with patient advocacy groups to inform feasibility assessments, protocol design, endpoint selection, and recruitment strategies. Supporting registries, natural history studies and patient communication strategies strengthens trial readiness and builds trust within the community. Open communication also clarifies eligibility expectations, reduces misconceptions and improves retention. By facilitating structured dialogue between sponsors and advocacy leaders, we align scientific objectives with patient priorities.

Operational expertise for rare disease trials

Managing long, complex neuromuscular trials require consistent site training, assessment standardization and risk mitigation strategies. Experience in rare disease recruitment, retention planning and pediatric inclusion is essential. We leverage our extensive global infrastructure and neuromuscular experience to manage these complexities.

End-to-end development support from early phase studies through later-stage trials enables sponsors to maintain continuity, quality and strategic alignment across the development life cycle. Combined with Thermo Fisher’s broader capabilities in laboratory services and scientific instrumentation, sponsors gain access to an integrated ecosystem designed to support both innovation and execution.

Turning momentum into meaningful outcomes

The CMT research landscape is evolving rapidly. Scientific understanding is deepening, industry engagement is growing and patient communities are ready.

For patients, success is not defined solely by a cure. Slowing disease progression, preserving independence and mobility, and improving daily quality of life represent meaningful and transformative outcomes. Even incremental progress can change the trajectory of a life.

The first successful therapy in CMT could validate the field, accelerate development pipelines and unlock possibilities for additional subtypes. With thoughtful trial design, strong collaboration, and sustained partnership, the coming decade holds real promise for transforming CMT from a condition managed primarily with supportive care to one with meaningful therapeutic options.